A Phase 2, Randomized, Dose-escalation, Ranibizumab-controlledStudy to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via One or Two Suprachoroidal Space (SCS) Injections in Participants with Neovascular Age-Relate
Clinical Trial Grant
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Regenxbio, Inc.
Start Date
February 19, 2025
End Date
December 31, 2029
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Regenxbio, Inc.
Start Date
February 19, 2025
End Date
December 31, 2029